SEARCH BY

Issuer directory Issuer directory
KEYWORDS
COMPANIES / ISIN
TYPE OF INFORMATION
INDUSTRY

Start search  ADVANCED SEARCH

COMPARTMENTS / INDICES

France
America
Asia
Oceania
Africa
Europe

CAC 40 NEWS

FEEDS

My RSS My Google Microsoft Live My Yahoo

PERIODIC INFORMATION

ANNUAL FINANCIAL REPORT

HALF-YEAR FINANCIAL

QUARTERLY INFORMATION

REGISTRATION DOCUMENT

20F

STATUTORY AUDITORS C

AGM

INTERNAL CONTROL

ANNUAL INFO MEMO ART

PERMANENT INFORMATION

2019.06.26 | 19:48 | Permanent Information Releases / Calendar

English version HTML (w) Mail

CHR. HANSEN

 Changes to the financial calendar 2018/19 - HTML (w)

2019.06.26 | 19:30 | Permanent Information Releases / Sales and Revenues

English version HTML (w) Mail

CHR. HANSEN

 Interim Report September 1, 2018 - May 31, 2019 - HTML (w)

2019.06.26 | 19:30 | Permanent Information Releases / General Company News

French version HTML (w) Mail

SANOFI-AVENTIS

 Sanofi : La FDA approuve Dupixent® (dupilumab) dans le traitement de la polypose nasosinusienne - HTML (w)

2019.06.26 | 19:30 | Permanent Information Releases / General Company News

English version HTML (w) Mail

SANOFI-AVENTIS

 Sanofi : FDA approves Dupixent® (dupilumab) for chronic rhinosinusitis with nasal polyposis - HTML (w)

+ More documents (280108)

Financial transactions

2019.06.26 | 19:48 | Permanent Information Releases / Calendar

English version HTML (w) Mail

CHR. HANSEN

 Changes to the financial calendar 2018/19 - HTML (w)

2019.06.26 | 19:30 | Permanent Information Releases / Sales and Revenues

English version HTML (w) Mail

CHR. HANSEN

 Interim Report September 1, 2018 - May 31, 2019 - HTML (w)

2019.06.26 | 19:30 | Permanent Information Releases / General Company News

French version HTML (w) Mail

SANOFI-AVENTIS

 Sanofi : La FDA approuve Dupixent® (dupilumab) dans le traitement de la polypose nasosinusienne - HTML (w)

2019.06.26 | 19:30 | Permanent Information Releases / General Company News

English version HTML (w) Mail

SANOFI-AVENTIS

 Sanofi : FDA approves Dupixent® (dupilumab) for chronic rhinosinusitis with nasal polyposis - HTML (w)

+ More documents (5466)